Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on August 17, 2016. The filing details the results of the Company's 2016 Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and stockholder voting results.
Material Changes and Corporate Actions
- Reverse Stock Split Approved: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split with a ratio between 8-to-1 and 12-to-1.
- Final Ratio Determined: Following the meeting, the Board of Directors selected a 1-for-12 reverse stock split ratio.
- Implementation Timeline: The split is anticipated to be effective on August 26, 2016, with trading on a split-adjusted basis commencing on August 29, 2016.
- Director Elections: All four nominees (Thomas K. Equels, Peter W. Rodino III, William M. Mitchell, and Stewart Appelrouth) were elected with significant majority support.
- Accountant Ratification: Stockholders ratified the selection of RSM US LLP as independent accountants.
- Executive Compensation: An advisory, non-binding vote on executive compensation was approved, though a notable portion of votes were cast against or abstained.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the reverse stock split mechanics. The primary operational change is the reduction of outstanding shares to increase the per-share price.
Investor Verification Checklist
- Verify the effective date of the 1-for-12 reverse stock split (August 26, 2016) and the start of adjusted trading (August 29, 2016).
- Confirm the impact of the reverse split on the number of shares held and the adjusted share price.
- Review the press release (Exhibit 99.1) referenced in the filing for additional details on the rationale for the split.
- Note that the filing entity is Hemispherx Biopharma, Inc., distinct from the "AIM Immunotech Inc." mentioned in the request metadata.